跳至主要内容
临床试验/NCT02024711
NCT02024711已完成不适用

EYEFILL® C.-US Viscoelastic Clinical Investigational Protocol- For Institutional Review Boards / Ethical Review Committees and Clinical Investigators

Bausch Health Americas, Inc.16 个研究点 分布在 1 个国家目标入组 262 人开始时间: 2013年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
262
试验地点
16
主要终点
Mean Percent Cell Change (Preservation of Endothelium)

研究概览

简要总结

The purpose of this multicenter, prospective, randomized clinical study is to determine the safety and effectiveness of the EYEFILL® C.-US Viscoelastic in patients undergoing cataract extraction and intraocular lens (IOL) implantation surgery.

EYEFILL® C.-US Viscoelastic is designed to create and maintain space, to protect the corneal endothelium and other intraocular tissues, and to manipulate tissues during surgery.

EYEFILL® C.-US Viscoelastic may also be used to coat intraocular lenses and instruments during cataract extraction and intraocular lens insertion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 21 years
  • Cataract requiring cataract extraction in at least 1 eye
  • Clear intraocular media other than cataract
  • Able to provide written informed consent
  • Able and willing to comply with required follow-up schedule
  • Competent to understand the procedure and the actions asked of him/her as a research subject

排除标准

  • Monocular
  • Ocular infection
  • History of glaucoma, Ocular Hypertension (IOP > 21 mmHg) likely to require IOP lowering medications, ocular condition requiring IOP lowering medication, condition preventing reliable Goldmann applanation tonometry, known steroid responder
  • Previous intraocular surgery in the operative eye
  • Previous serious corneal disease or known endothelial cell loss / damage (in operative eye)
  • History of chronic or recurrent inflammatory eye disease (in operative eye)
  • Evidence of retinal vascular disease (in operative eye)
  • Uncontrolled diabetes or proliferative diabetic retinopathy
  • Acute or chronic disease or illness that would increase the operative risk
  • Allergy to anesthetics or other postoperative medications
  • Known hypersensitivity to sodium hyaluronate or other components in viscoelastic
  • Patient in any other clinical trial within the 30 days prior to the start of the study

结局指标

主要结局

Mean Percent Cell Change (Preservation of Endothelium)

时间窗: Baseline, 3 months

Preservation of endothelium was assessed by specular microscope photographs to determine endothelial cell density.

次要结局

  • Percentage of Participants With Anterior Chamber Inflammation(3 months)
  • Percentage of Participants With Device-related Adverse Events Any Visit(3 months)
  • Percentage of Participants With Intraocular Pressure (IOP) Spikes >/= 30 mmHg Any Postoperative Visit(3 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验